NasdaqGM:VNDABiotechs
Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives
Vanda Pharmaceuticals (VNDA) opened Q1 2026 with total revenue of US$51.7 million and a basic EPS loss of US$0.82, while the trailing twelve months show revenue of US$217.8 million and a basic EPS loss of US$4.05. Over recent quarters the company has seen revenue move in a tight band between US$50.0 million and US$57.2 million and quarterly basic EPS losses range from US$0.08 to US$2.39. The latest figures fit into a pattern of steady sales alongside widening losses at the bottom line. For...